[{"address1": "Kungsbron 1, D5", "city": "Stockholm", "zip": "111 22", "country": "Sweden", "phone": "46 84 11 30 05", "website": "https://www.calliditas.se", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.", "fullTimeEmployees": 222, "companyOfficers": [{"maxAge": 1, "name": "Ms. Renee  Aguiar-Lucander", "age": 61, "title": "Chief Executive Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 11719000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fredrik  Johansson", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Lars  Stubberud", "age": 59, "title": "Vice President of Technical Operations", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Asa  Hillsten", "age": 48, "title": "Head of IR & Sustainability", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Gorman", "age": 47, "title": "Group General Counsel", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  Frithiof", "age": 48, "title": "Vice President of Human Resources", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann-Kristin  Myde BSc", "age": 68, "title": "Head of Clinical Development & VP of Project Management", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard S. Philipson M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Teona  Johnson", "title": "Head of US Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Ferraro", "title": "Head of US Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 40.24, "open": 40.45, "dayLow": 39.68, "dayHigh": 40.5, "regularMarketPreviousClose": 40.24, "regularMarketOpen": 40.45, "regularMarketDayLow": 39.68, "regularMarketDayHigh": 40.5, "beta": 1.457, "forwardPE": 6.3734174, "volume": 9713, "regularMarketVolume": 9713, "averageVolume": 9833, "averageVolume10days": 12180, "averageDailyVolume10Day": 12180, "marketCap": 1088232704, "fiftyTwoWeekLow": 15.25, "fiftyTwoWeekHigh": 42.1, "priceToSalesTrailing12Months": 0.67954487, "fiftyDayAverage": 39.22422, "twoHundredDayAverage": 27.485725, "currency": "USD", "enterpriseValue": 2395721472, "profitMargins": -0.29996002, "floatShares": 32252949, "sharesOutstanding": 27016700, "sharesShort": 8873, "sharesShortPriorMonth": 8367, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.00029999999, "heldPercentInstitutions": 0.03095, "shortRatio": 1.42, "shortPercentOfFloat": 0.0004, "bookValue": 1.977, "priceToBook": 20.374304, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -480364000, "trailingEps": -1.74, "forwardEps": 6.32, "enterpriseToRevenue": 1.496, "enterpriseToEbitda": -6.557, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CALT", "underlyingSymbol": "CALT", "shortName": "Calliditas Therapeutics AB", "longName": "Calliditas Therapeutics AB (publ)", "firstTradeDateEpochUtc": 1591363800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d7b9e28b-d147-3ca9-9029-b131dd8e88fd", "gmtOffSetMilliseconds": -14400000, "currentPrice": 40.28, "targetHighPrice": 40.0, "targetLowPrice": 39.0, "targetMeanPrice": 39.2, "targetMedianPrice": 39.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 5, "totalCash": 797278016, "totalCashPerShare": 14.762, "ebitda": -365368992, "totalDebt": 1008272000, "quickRatio": 2.373, "currentRatio": 2.686, "totalRevenue": 1601414016, "debtToEquity": 944.172, "revenuePerShare": 59.67, "returnOnAssets": -0.13405, "returnOnEquity": -1.57198, "freeCashflow": -210844624, "operatingCashflow": -244932000, "revenueGrowth": 1.078, "grossMargins": 0.93463, "ebitdaMargins": -0.22815001, "operatingMargins": -0.05628, "financialCurrency": "SEK", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]